May 2022

News

May 12, 2022

QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A. | Business Wire

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today…

Super User 0

Love0

News

May 12, 2022

Qiagen N.V. – QIAGEN acquires majority stake in enzymes provider BLIRT S.A.

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced…

Super User 0

Love0

News

May 12, 2022

Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis

- Data Presentation Today at 14th Myasthenia Gravis Foundation of America International Conference on Myasthenia…

Super User 0

Love0

News

May 12, 2022

Emmes launches Advantage eClinical as a standalone cloud native clinical technology platform

The cloud platform will empower biotech companies and CROs with an integrated solution for clinical…

Super User 0

Love0

News

May 12, 2022

BioBuzz Media Completes Inaugural University of Maryland Blockchain Accelerator Program

New blockchain talent marketplace seeks to solve hiring and diversity challenges in the rapidly growing…

Super User 0

Love0

The University of Maryland Adds $67M IDEA Factory To Its Innovation Ecosystem

News

May 12, 2022

University of Maryland Adds $67M IDEA Factory To Its Innovation Ecosystem

COLLEGE PARK, Md., May 10, 2022 /PRNewswire/ -- The University of Maryland today dedicated the…

Super User 0

Love0

News

May 12, 2022

ISPOR 2022 May 15-18, 2022 – Washington, DC, USA Area and Virtual

We are very excited for this year’s conference theme! Our theme will be a “green…

Super User 0

Love0

Cartesian Therapeutics to Present Late Breaking Data from Phase 1 2a Trial of RNA CAR T cell Therapy in Patients with Generalized Myasthenia Gravis Cartesian

News

May 12, 2022

Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis – Cartesian

GAITHERSBURG, Md., May 10, 2022 – Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA…

Super User 0

Love0

News

May 12, 2022

Virginia’s Pocket Life Science Ecosystems are Booming · BioBuzz

There is no doubt that Virginia is open for business to the life sciences industry.…

Super User 0

Love0

News

May 12, 2022

Trammell Crow Company Announces Plans for a Life Sciences Campus in Maryland

The Labs at Belward, located at the Belward Campus of The Johns Hopkins University, will…

Super User 0

Love0

QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A. | Business Wire

Qiagen N.V. – QIAGEN acquires majority stake in enzymes provider BLIRT S.A.

Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis

Emmes launches Advantage eClinical as a standalone cloud native clinical technology platform

BioBuzz Media Completes Inaugural University of Maryland Blockchain Accelerator Program

University of Maryland Adds $67M IDEA Factory To Its Innovation Ecosystem

ISPOR 2022 May 15-18, 2022 – Washington, DC, USA Area and Virtual

Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis – Cartesian

Virginia’s Pocket Life Science Ecosystems are Booming · BioBuzz

Trammell Crow Company Announces Plans for a Life Sciences Campus in Maryland

About BioHealth Innovation

Contact

Connect